Oak Ridge, TN – November 13, 2023 — Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces the presentation of data from a Phase I National Institute of Health (NIH) sponsored randomized control trial (RCT) from two Veterans Affairs Medical Centers (Boston , Minneapolis), validating treatment decisions guided by the Company’s BVA-100® diagnostic blood test benefitted patients with acute decompensated heart failure (ADHF).  Data were presented at the American Heart Association Scientific Sessions 2023 at the Pennsylvania Convention Center in Philadelphia, PA on November 11, 2023.

Key findings included:

• This successful pilot study paves the way for further funding opportunities tied to a Phase II project now that both the need for blood volume analysis (BVA) and the practicality of applying its results has been demonstrated 
• Data showed that on average 7 out of 10 ADHF patients are not being accurately diagnosed.  BVA was  more accurate than clinical assessment which was correct only 53% for volume and 56% for anemia
• A BVA-guided treatment protocol was successfully incorporated into the clinical workflow for ADHF
• Volume-appropriate treatment was significantly more likely in patients who received BVA-guided care showing that the results of BVA can be applied by clinicians in real-time in the clinical setting

The study titled, “Clinical Assessment of Volume Status in Heart Failure is Inaccurate at Detecting Hypervolemia and Anemia as Quantified by Blood Volume Measurement,” prospectively compared the standard of care treatment decisions (n=16) to those in a BVA-guided fluid management protocol (n=16). Clinical assessments of volume status and anemia were collected for all patients prior to BVA measurement at hospital admission and post-discharge. 

The results showed that the accuracy of volume status and anemia as determined by clinical assessment was only 53% and 56%, respectively, compared to BVA indicating that approximately 7 out of every 10 patients did not receive an accurate diagnosis of their volume condition.  “Volume management of both plasma and red blood cell volume is the cornerstone of heart failure care, and that care must start with an accurate diagnosis of the underlying problem which this data indicates does not happen in the vast majority of cases.  This data confirms other RCT pilot data that was independently presented by researchers from Duke University earlier this summer,” noted Jonathan Feldschuh, Daxor’s Chief Scientific Officer.